폐경전후 및 폐경후 골감소에서 호르몬대체요법과 Fluocalcic Effervescent® 병합치료 후 골밀도 및 골대사의 생화학 지표의 변화 = Changes of Bone Mineral Density and Biochemical Markers of Bone Turnover after Treatment with Hormone Replacement Therapy(HRT) and Fluocalcic Effervescent^(�) in Perimenopausal or Postmenopausal Osteopenia

다국어 초록 (Multilingual Abstract)

Background: Sodium fluoride stimulates bone formation and has been used to treat osteoporosis for decades despite debate about the antifracture efficacy. For women with low bone mass, the ideal therapy should not only inhibit bone resorption but simultaneously stimulate bone formation to increase the bone mass, the ideal therapy should not only inhibit bone resorption but simultaneously stimulate bone formation to increase the bone mass above the fracture threshold. We thus performed an intervention study to investigate the effect of a low dose fluoride prospectively, in combination with HRT, on bone mineral density (BMD) and biochemical markers of bone turnover. Methods: Thirty perimenopausal or postmenopausal osteopenic women were enrolled, and were treated with Fluocalcic effervescent® (disodium monofluorophophate [MFP] 100㎎ + calcium carbonate 1,250 ㎎) 1 tablet BID and conjugated equine estrogen (HRT) 0.625㎎ QD for 12 months in Department of Internal Medicine, Kosin University Gospel Hospital from January 2001 to December 2002. BMD and chemical markers of bone turnover, serum alkaline phosphatase, serum osteocalcin, and urine deoxypyridinoline(DPD), were evaluated before and 12 months after starting treatment. Results: Serum alkaline phosphatase, serum osteocalcin, and urine DPD after 12 months were not significantly different from those of pre-treatment values. The post-treatment BMD's but they were not correlated with all the pretreatment chemical markers of bone metabolism. Changes of the BMD of L2-L4 were not correlated with the changes of chemical markers except urine DPD. Pretreatment markers, BMD of L2-L4 , serum osteocalcin, serum alkaline phosphatase, and FSH were correlated with changes in BMD of L2-L4. There was no chemical markers correlated with the change in BMD of femoral neck. Conclusion: Twelve-month treatment with MFP and HRT was not associated with improvement in BMD. Pretreatment markers, BMD of L2-L4, serum osteocalcin, serum alkaline phosphatase, and FSH may predict changes in the BMD of L2-L4.